Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
medical: Archive
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PetIQ's (PETQ) first-quarter results are likely to reflect growth in the Product and Services segments of the business.
ALCNegative Net Change BPMCPositive Net Change ADVMNegative Net Change PETQPositive Net Change
medical medical-devices
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
by Zacks Equity Research
Cresco Labs' (CRLBF) rationalization and optimization efforts are expected to have had a positive impact on the company's first-quarter margins, profitability and cash flow.
ALCNegative Net Change GRTSNegative Net Change ERASNegative Net Change CRLBFPositive Net Change
earnings marijuana medical
Acadia Healthcare (ACHC) Shares Down 9% Despite Q1 Earnings Beat
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q1 results aided by improved revenue per patient day, partly offset by escalating costs. It continues to expect 2024 adjusted EPS within $3.40-$3.70.
MOHNegative Net Change CIPositive Net Change CNCNegative Net Change ACHCNegative Net Change
earnings medical
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
CPRXNegative Net Change ADVMNegative Net Change ARGXNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
ANI Pharmaceuticals (ANIP) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) revenues in the first quarter of 2024 are likely to have been driven by increased sales of its lead product, Cortrophin Gel, as well as growth in its generics business.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change ARGXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Waters (WAT) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Waters' (WAT) first-quarter 2024 results are likely to reflect strength in the large molecule and PFAS testing markets amid weakening demand in China.
NVDANegative Net Change WATNegative Net Change ANETPositive Net Change DCBONegative Net Change
earnings medical
Will These 5 Medical Device Stocks Beat This Earnings Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how INSP, MCK, FMS, NVRO and INGN are placed ahead of their earnings releases.
MCKNegative Net Change FMSPositive Net Change INGNPositive Net Change NVRONegative Net Change INSPNegative Net Change
earnings medical medical-devices
Should You Sell in May and Go Away? 5 ETF Strategies to Follow
by Sweta Killa
Investors might consider several investment strategies to navigate the May-October period more effectively that could lead to a winning portfolio.
XLPNegative Net Change VHTNegative Net Change VIGPositive Net Change VTVPositive Net Change QUALNo Net Change SPHQPositive Net Change USMVPositive Net Change IWDPositive Net Change SPLVPositive Net Change DGROPositive Net Change MGVPositive Net Change PAVEPositive Net Change
consumer-staples etfs medical utilities
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
ANIPNegative Net Change ANABPositive Net Change ARGXNegative Net Change IOVANegative Net Change
biotechs cell-therapy earnings medical
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Viatris' (VTRS) Q1 results are likely to gain from momentum in its branded and incremental revenues from new product launches.
CPRXNegative Net Change ANIPNegative Net Change ADVMNegative Net Change VTRSPositive Net Change
biotechs medical pharmaceuticals
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
by Riya Anand
SNDL's (SNDL) first-quarter performance is expected to benefit from reduced cost expenses and expansion into the liquor retail segment.
ALCNegative Net Change GRTSNegative Net Change SNDLNegative Net Change ERASNegative Net Change
earnings medical medical-devices
A Golden Opportunity to Enter U.S. Stock Markets: 5 Top Picks
by Nalak Das
We have narrowed our search to five U.S. corporate behemoths that have strong growth potential for 2024. These are: GOOGL, NFLX, AMZN, NOW, BSX.
AMZNNegative Net Change BSXNegative Net Change NFLXPositive Net Change NOWPositive Net Change GOOGLNegative Net Change
computers consumer-discretionary internet medical
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
MCKNegative Net Change ALCNegative Net Change FMSPositive Net Change RDNTNegative Net Change
medical medical-devices
Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y
by Zacks Equity Research
Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.
OMINegative Net Change OMCLNegative Net Change MEDPNegative Net Change EHCNegative Net Change
earnings medical medical-devices
5 Strong Picks to Ride the Wave of Relative Price Strength
by Nilanjan Choudhury
SKYW, POWL, MTX, COCO and THC are five stocks with explosive relative price strength.
COCOPositive Net Change THCNegative Net Change SKYWPositive Net Change MTXPositive Net Change POWLPositive Net Change
basic-materials consumer-staples industrial-products medical transportation
New Strong Buy Stocks for May 6th
by Zacks Equity Research
ROOT, SMCI, PPC, DFH and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2024.
DVANegative Net Change PPCPositive Net Change SMCIPositive Net Change ROOTNegative Net Change DFHNegative Net Change
computers home-builder medical
The Zacks Analyst Blog Highlights AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes
by Zacks Equity Research
AstraZeneca, Qualcomm, FedEx, American International and Baker Hughes are included in this Analyst Blog.
AZNPositive Net Change QCOMPositive Net Change AIGNegative Net Change FDXNegative Net Change BKRNegative Net Change
medical
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Centene and Humana
by Zacks Equity Research
UnitedHealth, The Cigna, Centene and Humana have been highlighted in this Industry Outlook article.
UNHPositive Net Change HUMNegative Net Change CIPositive Net Change CNCNegative Net Change
medical
New Strong Sell Stocks for May 6th
by Zacks Equity Research
DDD, ASO and CVS have been added to the Zacks Rank #5 (Strong Sell) List on May 6, 2024.
CVSNegative Net Change DDDNegative Net Change ASONegative Net Change
medical
Best Value Stocks to Buy for May 6th
by Zacks Equity Research
DFH, DVA and BDC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 6, 2024.
DVANegative Net Change BDCPositive Net Change DFHNegative Net Change
medical
Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change AVNSPositive Net Change
earnings medical medical-devices
Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up
by Zacks Equity Research
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change SRDXNegative Net Change
earnings medical medical-devices
Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
by Zacks Equity Research
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
REGNNegative Net Change ALNYNegative Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up
by Zacks Equity Research
Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.
BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change HOLXNegative Net Change
earnings medical medical-devices
Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.
BSXNegative Net Change ALGNNegative Net Change RMDNegative Net Change LNTHNegative Net Change
earnings medical medical-devices